About Glucose-fructose oxidoreductase domain-containing protein 2
Glucose-fructose oxidoreductase domain-containing protein 2 (GFOD2) is a protein
from Homo sapiens identified by UniProt accession
Q3B7J2, 385 residues long.
MolForge cross-references it against 0 known binders and
23 disease associations.
Target properties
| Protein name | Glucose-fructose oxidoreductase domain-containing protein 2 |
| UniProt accession | Q3B7J2 |
| Gene | GFOD2 |
| Organism | Homo sapiens |
| Length | 385 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (23)
Diseases linked to this target (Open Targets).
- lean body mass · score 0.12
- red blood cell density measurement · score 0.09
- balding measurement · score 0.06
- mean corpuscular hemoglobin concentration · score 0.05
- erythrocyte count · score 0.04
- high density lipoprotein cholesterol measurement · score 0.04
- hemoglobin measurement · score 0.03
- hematocrit · score 0.03
- refractive error · score 0.03
- sleep duration · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q3B7J2-F1 | alphafold | PREDICTED | 91.97 | — |
Amino-acid sequence (385 residues)
MKMLPGVGVF GTGSSARVLV PLLRAEGFTV EALWGKTEEE AKQLAEEMNI AFYTSRTDDI LLHQDVDLVC ISIPPPLTRQ ISVKALGIGK NVVCEKAATS VDAFRMVTAS RYYPQLMSLV GNVLRFLPAF VRMKQLISEH YVGAVMICDA RIYSGSLLSP SYGWICDELM GGGGLHTMGT YIVDLLTHLT GRRAEKVHGL LKTFVRQNAA IRGIRHVTSD DFCFFQMLMG GGVCSTVTLN FNMPGAFVHE VMVVGSAGRL VARGADLYGQ KNSATQEELL LRDSLAVGAG LPEQGPQDVP LLYLKGMVYM VQALRQSFQG QGDRRTWDRT PVSMAASFED GLYMQSVVDA IKRSSRSGEW EAVEVLTEEP DTNQNLCEAL QRNNL
Explore Glucose-fructose oxidoreductase domain-containing protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets